Zobrazeno 1 - 10
of 209
pro vyhledávání: '"Mallesara, G."'
Autor:
Mahon KL; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.; Prostate Cancer Research Group, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Sutherland SI; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.; Prostate Cancer Research Group, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Cancer Research Group, The ANZAC Research Institute, Sydney, New South Wales, Australia., Lin HM; Prostate Cancer Research Group, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; School of Clinical Medicine, University of NSW, Sydney, New South Wales, Australia., Stockler MR; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia., Gurney H; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Calvary Mater, Newcastle, New South Wales, Australia., Mallesara G; Medical Oncology Department, Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia., Briscoe K; Northern Haematology Oncology Group, Sydney, New South Wales, Australia., Marx G; BC Cancer Agency, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Higano CS; Royal Marsden Hospital and Institute of Cancer Research, London, UK., de Bono JS; St Vincent's Centre for Applied Medical Research, Sydney, New South Wales, Australia., Chi KN; Royal Marsden Hospital and Institute of Cancer Research, London, UK., Clark G; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; Cancer Research Group, The ANZAC Research Institute, Sydney, New South Wales, Australia., Breit SN; School of Clinical Medicine, University of NSW, Sydney, New South Wales, Australia.; Concord Hospital, Sydney, New South Wales, Australia., Brown DA; School of Clinical Medicine, University of NSW, Sydney, New South Wales, Australia.; Concord Hospital, Sydney, New South Wales, Australia., Horvath LG; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.; Prostate Cancer Research Group, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.; School of Clinical Medicine, University of NSW, Sydney, New South Wales, Australia.
Publikováno v:
The Prostate [Prostate] 2024 Jun; Vol. 84 (8), pp. 747-755. Date of Electronic Publication: 2024 Mar 27.
Autor:
Day F; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia., Sridharan S; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, Australia., Johnson C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia., Quah GT; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia., Mallesara G; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia., Kumar M; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, Australia., Poulter AL; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia., Morrison A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia., van der Westhuizen A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia., Fraser A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, Australia., Oldmeadow C; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.; Clinical Research Design, Information Technology and Statistical Support Unit, Hunter Medical Research Institute, New Lambton Heights, Australia., Martin J; School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, Australia.
Publikováno v:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2024 Jun; Vol. 20 (3), pp. 416-422. Date of Electronic Publication: 2024 Mar 21.
Autor:
Luke JJ; UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA. lukejj@upmc.edu., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Blumenschein GR; Department of Thoracic Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Chmielowski B; Division of Hematology & Medical Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Ulahannan SV; OUHSC Oklahoma City, OK/SCRI, Oklahoma City, OK, USA., Connolly RM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.; Cancer Research at UCC, College of Medicine and Health, University College Cork, Cork, Ireland., Santa-Maria CA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Wang J; Duke University Medical Center, Durham, NC, USA., Bahadur SW; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Weickhardt A; Austin Health, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia., Asch AS; OUHSC Oklahoma City, OK/SCRI, Oklahoma City, OK, USA., Mallesara G; Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia., Clingan P; Southern Medical Day Care Centre, Wollongong, New South Wales, Australia., Dlugosz-Danecka M; Pratia MCM Krakow, Krakow, Poland., Tomaszewska-Kiecana M; BioVirtus Research Site Sp. Z o.o., Jozefow, Poland., Pylypenko H; Cherkasy Regional Oncology, Cherkasy, Ukraine., Hamad N; St. Vincent's Health Network, Kinghorn Cancer Centre, University of New South Wales, School of Clinical Medicine, Faculty of Medicine and Health, University of Notre Dame Australia, School of Medicine, Sydney, New South Wales, Australia., Kindler HL; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA., Sumrow BJ; MacroGenics, Clinical, Rockville, MD, USA., Kaminker P; MacroGenics, Research, Rockville, MD, USA., Chen FZ; MacroGenics, Research, Brisbane, CA, USA., Zhang X; MacroGenics, Research, Rockville, MD, USA., Shah K; MacroGenics, Research, Rockville, MD, USA., Smith DH; MacroGenics, Research, Brisbane, CA, USA., De Costa A; MacroGenics, Research, Brisbane, CA, USA., Li J; MacroGenics, Research, Brisbane, CA, USA., Li H; MacroGenics, Clinical, Rockville, MD, USA., Sun J; MacroGenics, Clinical, Rockville, MD, USA., Moore PA; MacroGenics, Research, Rockville, MD, USA.; Zymeworks, Vancouver, British Columbia, Canada.
Publikováno v:
Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2814-2824. Date of Electronic Publication: 2023 Oct 19.
Autor:
Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, 390 Victoria Street, Sydney, NSW 2010, Australia.; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; Garvan Institute of Medical Research, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., John N; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Pathmanandavel S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; Garvan Institute of Medical Research, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., Counter W; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Ayers M; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Sharma S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Agrawal S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Poole A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Hovey E; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia., Pranavan G; Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia., Gedye C; Calvary Mater Hospital, Newcastle, NSW, Australia., Mallesara G; Calvary Mater Hospital, Newcastle, NSW, Australia., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia., Lee A; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Hickey A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Eu P; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Joshua AM; The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia., Crumbaker M; Garvan Institute of Medical Research, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.; The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Publikováno v:
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 01; Vol. 15, pp. 17588359231156392. Date of Electronic Publication: 2023 Mar 01 (Print Publication: 2023).
Autor:
Day F; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia. fiona.day@calvarymater.org.au.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia. fiona.day@calvarymater.org.au.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. fiona.day@calvarymater.org.au., Sridharan S; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia., Lynam J; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Johnson C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Fraser A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia., Thompson SR; Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia., Michael M; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Leong T; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Roy A; Flinders Medical Centre, Bedford Park, Adelaide, SA, Australia., Kumar M; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia., van der Westhuizen A; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Quah GT; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Mandaliya H; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Mallesara G; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Sappiatzer J; GenesisCare, Flinders Private Hospital, Bedford Park, Adelaide, SA, Australia., Oldmeadow C; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Martin J; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.
Publikováno v:
BMC cancer [BMC Cancer] 2022 Dec 17; Vol. 22 (1), pp. 1324. Date of Electronic Publication: 2022 Dec 17.
Background: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. Methods: KEYNOTE-048 was a randomised, phase 3 study of participants with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::25cb1f03a8d1b22885303ced3a20f10f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121788
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121788
Autor:
Travers A; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Adler K; Medical Oncology Trial Unit, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Blanchard G; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Bonaventura T; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.; Newcastle Private Hospital, Newcastle, New South Wales, Australia., Charlton J; Epic Pharmacy Newcastle, Newcastle, New South Wales, Australia., Day F; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Healey L; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Kim S; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Lombard J; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.; Newcastle Private Hospital, Newcastle, New South Wales, Australia., Mallesara G; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.; Newcastle Private Hospital, Newcastle, New South Wales, Australia., Mandaliya H; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.; Newcastle Private Hospital, Newcastle, New South Wales, Australia., Navani V; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Nordman I; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Paterson R; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.; Newcastle Private Hospital, Newcastle, New South Wales, Australia., Plowman L; Medical Oncology Trial Unit, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Quah GT; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Scalley M; Newcastle Private Hospital, Newcastle, New South Wales, Australia.; Epic Pharmacy Newcastle, Newcastle, New South Wales, Australia., Shrestha P; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Tailor B; Clinical Systems Team, Hunter New England Local Health District, Newcastle, New South Wales, Australia., van der Westhuizen A; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Zhang B; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Lynam J; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.; Newcastle Private Hospital, Newcastle, New South Wales, Australia.
Publikováno v:
Internal medicine journal [Intern Med J] 2021 May; Vol. 51 (5), pp. 673-681.
Autor:
Martin, J., Fiona, D., Loh, J., Ackland, S., Bonaventura, T., Fay, M., Kumar, M., Lynam, J., Mallesara, G., O'Neill, M., Smart, J., Van der Westhuizen, A., Wills, V., Wright, T.
Publikováno v:
In Radiotherapy and Oncology April 2019 133 Supplement 1:S769-S770
Publikováno v:
In Journal of Thoracic Oncology October 2018 13(10) Supplement:S875-S875
Autor:
Liu, Qiang1 (AUTHOR), Guan, Yujing2,3,4 (AUTHOR), Li, Shenglong2,3,4 (AUTHOR) slli@cmu.edu.cn
Publikováno v:
Molecular Cancer. 9/2/2024, Vol. 23 Issue 1, p1-26. 26p.